Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. C.i. 45350
2. Colircusi Fluoresceina
3. D And C Yellow No. 7
4. D And C Yellow No. 8
5. Diofluor
6. Dipotassium Salt, Fluorescein
7. Disodium Fluorescein
8. Disodium Salt, Fluorescein
9. Fluor I Strip A.t.
10. Fluor-i-strip A.t.
11. Fluorescine Sodique Faure
12. Fluorescein Dipotassium Salt
13. Fluorescein Disodium Salt
14. Fluorescein Monosodium Salt
15. Fluorescein Sodium, Minims
16. Fluorescein, Disodium
17. Fluorescein, Sodium
18. Fluoresceina, Colircusi
19. Fluoresceine, Minims
20. Fluorescite
21. Fluorets
22. Ful Glo
23. Ful-glo
24. Funduscein
25. Minims Fluorescein Sodium
26. Minims Fluoresceine
27. Minims Stains
28. Monosodium Salt, Fluorescein
29. Optifluor Diba
30. Sodium Fluorescein
31. Sodium, Fluorescein
32. Uranine
1. 2321-07-5
2. Solvent Yellow 94
3. Resorcinolphthalein
4. Yellow Fluorescein
5. Fluoresceine
6. 3',6'-dihydroxy-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one
7. 3,6-fluorandiol
8. D&c Yellow No. 7
9. Japan Yellow 201
10. D And C Yellow No. 7
11. C.i. Solvent Yellow 94
12. 3',6'-dihydroxyfluoran
13. Fluorescein Acid
14. Fluoreszein
15. Soap Yellow F
16. Hidacid Fluorescein
17. Resorcinol Phthalein
18. D & C Yellow No. 7
19. D+c Yellow No. 7
20. 9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone
21. Fluorescein (free Acid)
22. 11712 Yellow
23. Chebi:31624
24. 9-(o-carboxyphenyl)-6-hydroxy-3h-xanthen-3-one
25. Japan Yellow No. 201
26. Zlut Kysela 73
27. 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
28. Fluoran, 3',6'-dihydroxy-
29. Nsc 667256
30. 3',6'-fluorandiol
31. C.i. 45350:1
32. Mfcd00005050
33. Tpy09g7xir
34. Spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one, 3',6'-dihydroxy-
35. Chembl1057
36. Ci 45350:1
37. 3h-xanthen-3-one, 9-(o-carboxyphenyl)-6-hydroxy-
38. Nsc667256
39. Benzoic Acid, O-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-
40. Nsc-667256
41. Nsc-759114
42. Benzoic Acid, 2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-
43. Ncgc00161643-03
44. 3',6'-dihydroxyspiro(isobenzofuran-1(3h),9'(9h)-xanthen)-3-one
45. 3',6'-dihydroxyspiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one
46. Spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',6'-dihydroxy-
47. 3,6-dihydroxyspiro(xanthene-9,3'-phthalide)
48. Dsstox_cid_18887
49. Dsstox_rid_79416
50. Dsstox_gsid_38887
51. 3',6'-dihydroxy-3h-spiro[2-benzofuran-1,9'-xanthen]-3-one
52. Fluorescein Red
53. Cas-2321-07-5
54. 3,6-dihydroxyspiro[xanthene-9,3'-phthalide]
55. Zlut Kysela 73 [czech]
56. Fluorecein
57. Diofluor
58. Ccris 7076
59. Hsdb 2128
60. Fluorescite (tn)
61. Diresorcinolphthalein
62. Einecs 219-031-8
63. Brn 0094324
64. Fluorescite (salt/mix)
65. 3',6' Dihydroxyfluoran
66. Fluorescein (jan/usp)
67. Fluorescein [ii]
68. Fluorescein [mi]
69. Unii-tpy09g7xir
70. Fluorescein [jan]
71. Fluorescein [hsdb]
72. Epitope Id:137337
73. Upcmld-dp087
74. Yellow 7 [inci]
75. Fluorescein [vandf]
76. Fluorescein [mart.]
77. Schembl16533
78. Fluorescein [usp-rs]
79. Fluorescein [who-dd]
80. Fluorescein [usp:ban:jan]
81. Ki201 [inci]
82. Dtxsid0038887
83. Upcmld-dp087:001
84. Acid Yellow 73 [inci]
85. Gnbhrkfjiuuoqi-uhfffaoysa-
86. Fluorescein (solvent Yellow 94)
87. C.i. 45350 (salt/mix)
88. Fluorescein [ep Monograph]
89. Hms2093f21
90. Hms3744c17
91. Moli001003
92. Pharmakon1600-01505396
93. Fluorescein [usp Monograph]
94. Amy22388
95. Hy-d0251
96. Zinc3860453
97. Tox21_113500
98. Tox21_303508
99. Bdbm50237588
100. C.i. Acid Yellow 73 (salt/mix)
101. Nsc759114
102. S5488
103. Spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one,3'6'-dihydroxy-
104. Akos015903296
105. Ccg-213417
106. Cs-7537
107. Db00693
108. C.i. 45350a
109. Fluorescein, For Fluorescence, Free Acid
110. Ncgc00161643-01
111. Ncgc00161643-02
112. Ncgc00257491-01
113. D & C Yellow No. 7 K7133
114. Sy012645
115. Sbi-0206827.p001
116. F0095
117. Fluorescein (free Acid), Dye Content 95 %
118. Ft-0668579
119. D01261
120. D70685
121. Ec 219-031-8
122. Ab00643381_02
123. 5-19-06-00456 (beilstein Handbook Reference)
124. Q410922
125. Sr-05000001696
126. Sr-05000001696-1
127. W-107417
128. Brd-k21913543-001-01-6
129. 3',6'-dihydroxyspiro[isobenzofuran-3,9'-xanthene]-1-one
130. E89fa0b4-4844-46a2-af9b-29eca50e5599
131. Fluorescein, European Pharmacopoeia (ep) Reference Standard
132. 3',6'-dihydroxy-3h-spiro[isobenzo[b]furan-1,9'-xanthen]-3-one
133. Fluorescein, United States Pharmacopeia (usp) Reference Standard
134. Fluorescein Low Range Dna Standard, Fluorescein-labeled Marker For Dna Electrophoresis
135. Spiro[isobenzofuran-1(3h),9'-[9h]xanthene]-ar-carboxylicacid, 3',6'-dihydroxy-3-oxo-
| Molecular Weight | 332.3 g/mol |
|---|---|
| Molecular Formula | C20H12O5 |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 0 |
| Exact Mass | 332.06847348 g/mol |
| Monoisotopic Mass | 332.06847348 g/mol |
| Topological Polar Surface Area | 76 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 522 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Fluorescite |
| PubMed Health | Fluorescein (Injection) |
| Drug Classes | Disclosing Agent |
| Drug Label | FLUORESCITE (fluorescein injection, USP) 10% contains fluorescein sodium (equivalent to fluorescein 10% w/v). It is a sterile solution for use intravenously as a diagnostic aid. Its chemical name is spiro[isobenzofuran-1(3H), 9'-[9H]xanthene]-3-one.. |
| Active Ingredient | Fluorescein sodium |
| Dosage Form | Injectable |
| Route | Intravenous |
| Strength | eq 500mg base/5ml (eq 100mg base/ml) |
| Market Status | Prescription |
| Company | Alcon Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Fluorescite |
| PubMed Health | Fluorescein (Injection) |
| Drug Classes | Disclosing Agent |
| Drug Label | FLUORESCITE (fluorescein injection, USP) 10% contains fluorescein sodium (equivalent to fluorescein 10% w/v). It is a sterile solution for use intravenously as a diagnostic aid. Its chemical name is spiro[isobenzofuran-1(3H), 9'-[9H]xanthene]-3-one.. |
| Active Ingredient | Fluorescein sodium |
| Dosage Form | Injectable |
| Route | Intravenous |
| Strength | eq 500mg base/5ml (eq 100mg base/ml) |
| Market Status | Prescription |
| Company | Alcon Pharms |
Contrast Medium
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
VET: Deep corneal ulcers, descemetocele, and iris prolapse are seen with some frequency in dogs, cats, and horses. ... Important diagnostic aids are the Schirmer tear test to measure aqueous tear production and topical fluorescein to examine the corneal ulcer. ...
Kahn, C.M. (Ed.); The Merck Veterinary Manual 9th ed. Merck & Co. Whitehouse Station, NJ. 2005, p. 1416
Fluorescein is now sometimes used for determination of circulation time, adequacy of blood supply, and viability of tissue.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1004
In determination of circulation time, ... by rapid iv ... appearance of fluorescence in lips, eyes, or intact skin or in wheals (histamine or scratch) ... is taken as end point.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1004
Measurement of arm-to-retina circulation time is employed for diagnosis of carotid artery occlusion.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 985
Adverse effects following topical administration to the eye may include irritation and rash. Fluorescein may cause yellow discoloration of skin or eyes. urine may attain a bright yellow color. Adverse effects following intravenous administration include nausea, vomiting, headache, dizziness, fainting, and low blood pressure.
United States Pharmacopeial Convention, Inc (USP); MSDS Database Online; Material Safety Data Sheet: Fluorescein; Catalog Number: 1277004; (Revision Date: January 31, 2005)
For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
Fluorescent Dyes
Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)
S01JA01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01J - Diagnostic agents
S01JA - Colouring agents
S01JA01 - Fluorescein
Absorption
Rapidly distributed
Route of Elimination
Fluorescein and its metabolites are mainly eliminated via renal excretion.
Volume of Distribution
0.5 L/kg
Clearance
renal cl=1.75 mL/min/kg [After IV administration]
hepatic cl=1.50 mL/min/kg [After IV administration]
Fluorescence of skin persists for several hr, and dye appears in urine for as long as 30 hr.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1004
Within 7 to 14 seconds after IV administration into antecubital vein, fluorescein usually appears in the central artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade after 6 to 12 hours of dosing. Various estimates of volume of distribution indicate that fluorescein distributes well into interstitial space (0.5 L/ kg).
US Natl Inst Health; DailyMed. Current Medication Information for Fluorescite (fluorescein sodium) injection, solution (2009). Available from, as of October 19, 2009: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Fluorescein+sodium
Fluorescein and its metabolites are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.
US Natl Inst Health; DailyMed. Current Medication Information for Fluorescite (fluorescein sodium) injection, solution (2009). Available from, as of October 19, 2009: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Fluorescein+sodium
Fluorescein sodium has been demonstrated to be excreted in human milk.
US Natl Inst Health; DailyMed. Current Medication Information for Fluorescite (fluorescein sodium) injection, solution (2009). Available from, as of October 19, 2009: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Fluorescein+sodium
The permeability of the blood-retinal and blood-aqueous barriers to fluorescein and the rate of aqueous flow can be estimated by measurements of fluorescein in the vitreous, aqueous, and plasma after systemic administration. Fluorescein is commonly measured by fluorescence, but fluorescein glucuronide, a metabolite of fluorescein, also fluoresces. To assess the influence of fluorescein glucuronide on the quantitation of fluorescein by fluorescence, we studied the pharmacokinetics of fluorescein and fluorescein glucuronide for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. The plasma and the plasma ultrafiltrate were measured by fluorescence and by high performance liquid chromatography. In our fluorophotometer, fluorescein glucuronide was 0.124 times as fluorescent as fluorescein. Fluorescein was rapidly converted to fluorescein glucuronide, and within 10 min the concentration of unbound fluorescein glucuronide exceeded that of unbound fluorescein. The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, so that fluorescein glucuronide contributed almost all of the plasma fluorescence after 4-5 hr. Because fluorescein glucuronide was less bound in the plasma than fluorescein, the ratio of the fluorescence of the plasma ultrafiltrate to that of the plasma increased with time. The greatest proportion of the total fluorescein available to penetrate into the ocular compartments occurred shortly after injection. ...
PMID:3721789 Blair NP et al; Invest Ophthalmol Vis Sci 27 (7): 1107-14 (1986).
The permeability of the blood-retinal and blood-aqueous barriers to fluorescein and the rate of aqueous flow can be estimated by measurements of fluorescein in the vitreous, aqueous, and plasma after systemic administration. Fluorescein is commonly measured by fluorescence, but fluorescein glucuronide, a metabolite of fluorescein, also fluoresces. To assess the influence of fluorescein glucuronide on the quantitation of fluorescein by fluorescence, we studied the pharmacokinetics of fluorescein and fluorescein glucuronide for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. The plasma and the plasma ultrafiltrate were measured by fluorescence and by high performance liquid chromatography. In our fluorophotometer, fluorescein glucuronide was 0.124 times as fluorescent as fluorescein. Fluorescein was rapidly converted to fluorescein glucuronide, and within 10 min the concentration of unbound fluorescein glucuronide exceeded that of unbound fluorescein. The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, so that fluorescein glucuronide contributed almost all of the plasma fluorescence after 4-5 hr. Because fluorescein glucuronide was less bound in the plasma than fluorescein, the ratio of the fluorescence of the plasma ultrafiltrate to that of the plasma increased with time. The greatest proportion of the total fluorescein available to penetrate into the ocular compartments occurred shortly after injection. ...
PMID:3721789 Blair NP et al; Invest Ophthalmol Vis Sci 27 (7): 1107-14 (1986).
Fluorescein undergoes rapid metabolism to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose, indicating relatively rapid conjugation.
US Natl Inst Health; DailyMed. Current Medication Information for Fluorescite (fluorescein sodium) injection, solution (2009). Available from, as of October 19, 2009: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Fluorescein+sodium
Fluorescein is a known human metabolite of zinc15020070.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
... The pharmacokinetics of fluorescein and fluorescein glucuronide /were studied/ for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. ... The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, ... .
PMID:3721789 Blair NP et al; Invest Ophthalmol Vis Sci 27 (7): 1107-14 (1986).
Fluorescein sodium is used extensively as a diagnostic tool in the field of ophthalmology. Fluorescein is a fluorescent compound or fluorophore having a maximum absorbance of 494 m and an emission maximum of 521 nm. The yellowish-green fluorescence of the compound can be used to demarcate the vascular area under observation, distinguishing it from adjacent areas. It is applied topically in the form of a drop or it can be injected intravenously to produce a fluorescein angiogram. Topical fluorescein is a useful tool in the diagnosis of corneal abrasions, corneal ulcers, herpetic corneal infections, and dry eye. Fluorescein angiography is used to diagnose and categorize macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors.
Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures. /Fluorescein sodium/
US Natl Inst Health; DailyMed. Current Medication Information for Fluorescite (fluorescein sodium) injection, solution (2009). Available from, as of October 19, 2009: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Fluorescein+sodium
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.4%;0.2...DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.4%;0.25%
USFDA APPLICATION NUMBER - 208582
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.4%;0.3...DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.4%;0.3%
USFDA APPLICATION NUMBER - 211039
Related Excipient Companies
Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Solubilizers
Granulation
Direct Compression
Parenteral
Controlled & Modified Release
Coating Systems & Additives
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Topical
Film Formers & Plasticizers
Co-Processed Excipients
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2037-11-15
BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM
US Patent Number : 10842872
Drug Substance Claim :
Drug Product Claim :
Application Number : 211039
Patent Use Code : U-3001
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-11-15
Patent Expiration Date : 2037-11-15
BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM
US Patent Number : 10293047
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 211039
Patent Use Code : U-2755
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-11-15
Patent Expiration Date : 2037-11-15
BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM
US Patent Number : 10632197
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 211039
Patent Use Code : U-2755
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-11-15
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
